Blueblood Ventures Annual Report: Profit Reported Amidst Regulatory Crisis

Profit After Tax stood at Rs 3.26 lakh, while advances pending confirmation reached Rs 63.46 crore.

Reader Takeaway: Profit remains minimal while delisting risk and asset recovery concerns create severe capital liquidity pressure.

What just happened

Blueblood Ventures Ltd has published its 19th Annual Report for FY 2025-26. The company reported a modest net profit of Rs 3.26 lakh, up from Rs 0.59 lakh in the previous year, on a total revenue of Rs 110.64 lakh. Despite the positive bottom-line trend, the report highlights critical failures in corporate governance and regulatory compliance.

Why this matters

The company’s stock remains suspended from trading on the BSE since November 21, 2022, due to non-compliance with SEBI regulations. Furthermore, on December 19, 2025, the BSE issued a Show Cause Notice (SCN) proposing the compulsory delisting of the company's shares. This creates a severe liquidity trap for existing shareholders who cannot exit their positions easily.

The backstory

The trading suspension stems from failure to comply with Regulation 76 of the SEBI (Depositories and Participants) Regulations. While the company filed a waiver application on June 24, 2026, to stop the delisting process, the matter remains pending. Simultaneously, the company failed to appoint an internal auditor for the second consecutive year, violating Section 138 of the Companies Act.

Risks to watch

Auditors have flagged significant concerns regarding the balance sheet. This includes unconfirmed debit balances for advances amounting to Rs 63.46 crore. Additionally, the company is in the process of reclaiming 247 Zero Coupon Optional Convertible Debentures (ZOCDs) valued at Rs 11.55 crore that were allegedly transferred to an external party incorrectly.

Context metrics (time-bound)

The company operates with a limited workforce of fewer than five employees and maintains no subsidiaries or joint ventures as of March 31, 2026. Management has cited delays in statutory approvals as the primary reason for the lack of new business development during the fiscal year.

What to track next

Investors should closely monitor the outcome of the revocation application regarding the trading suspension and any official communication from the BSE regarding the delisting proposal. The recovery of the Rs 63.46 crore in advances and the disputed ZOCDs are critical for the company's financial stability.